New pill could keep early breast cancer from coming back
NCT ID NCT07349069
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial compares a new drug, HRS-8080, against standard hormone therapies (like letrozole or tamoxifen) in 5,500 women with intermediate or high risk early breast cancer who have already completed at least 2 years of standard hormone treatment. The goal is to see if HRS-8080 better prevents the cancer from returning or spreading. Participants will be randomly assigned to receive either HRS-8080 or a standard therapy for up to 5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-8080 tablets
- What this could lead to
- If successful, this could offer a more effective treatment option to reduce the risk of breast cancer returning in patients with intermediate or high risk early breast cancer.
- What could go wrong
- This is a large Phase 3 trial, but results are not yet available. HRS-8080 may not prove better than standard therapies, and side effects are possible. The study is still recruiting, so outcomes are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- A dab of gel on the breathing tube might spare surgery patients a sore throat — a trial puts it to the test.
- Can a deeper nerve block ease pain after breast surgery?
- Does breast cancer radiation harm a key immune gland? a study investigates
- A web program may ease the emotional toll of chemotherapy hair loss
- Can 3D breast imaging spot more dangerous cancers than standard mammograms?